Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide, Dapagliflozin, and Acarbose for Cognitive and Olfactory Function in T2DM
NCT03961659Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of liraglutide, dapagliflozin and acarbose in type 2 diabetes mellitus (T2DM) and cognitive impairment, sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cognitive impairment
Beyond the preview
Go deeper on NCT03961659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961659.